Skip to main content

The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers

Publication ,  Journal Article
Lemieux, J; Clemons, M; Provencher, L; Dent, S; Latreille, J; Mackey, J; Pritchard, KI; Rayson, D; Verma, S; Wang, B; Chia, S
Published in: Current Oncology
January 1, 2009

Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with early-stage breast cancer positive for the human epidermal growth factor receptor 2 (HER2), questions have been raised about the use of trastuzumab in the neoadjuvant setting. The present paper reviews the currently available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents in the neoadjuvant setting. The panel focussed on • the use of trastuzumab and other HER2-targeted agents as neoadjuvant therapy in primary operable, locally advanced, and inflammatory breast cancer; and • possible choices of chemotherapeutic regimens with trastuzumab. The suggestions described here will continue to evolve as data from current and future trials with trastuzumab and other HER2-targeted agents emerge. Copyright © 2009 Multimed Inc.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Current Oncology

DOI

EISSN

1718-7729

Publication Date

January 1, 2009

Volume

16

Issue

5

Start / End Page

48 / 57

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lemieux, J., Clemons, M., Provencher, L., Dent, S., Latreille, J., Mackey, J., … Chia, S. (2009). The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers. Current Oncology, 16(5), 48–57. https://doi.org/10.3747/co.v16i5.510
Lemieux, J., M. Clemons, L. Provencher, S. Dent, J. Latreille, J. Mackey, K. I. Pritchard, et al. “The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers.” Current Oncology 16, no. 5 (January 1, 2009): 48–57. https://doi.org/10.3747/co.v16i5.510.
Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J, et al. The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers. Current Oncology. 2009 Jan 1;16(5):48–57.
Lemieux, J., et al. “The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers.” Current Oncology, vol. 16, no. 5, Jan. 2009, pp. 48–57. Scopus, doi:10.3747/co.v16i5.510.
Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J, Pritchard KI, Rayson D, Verma S, Wang B, Chia S. The role of neoadjuvant HER2-targeted therapies in HER2-overexpressing breast cancers. Current Oncology. 2009 Jan 1;16(5):48–57.

Published In

Current Oncology

DOI

EISSN

1718-7729

Publication Date

January 1, 2009

Volume

16

Issue

5

Start / End Page

48 / 57

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis